enzalutamide,talazoparib,olaparib
astellas,pfizer,Astrazeneca,Merck
['talapro,2', ' ola ', 'brca', 'talazo', 'crpc', 'talapro2', 'brca p']
summary oral abstract prost session(part 2):
-capture study: brca pts had significantly less pfs, pfs2, and os in mcrpc
-talapro2: talazoparib + enza significantly improves rpfs vs enza in hrrm. mos nr vs 33.7m hr 0.69 p=0.068
-lu plus ola has promising activity in mcrpc #asco23
Medical oncologist. Clinical researcher focused in GU tumors. Associate Professor UCM. Hospital Clinico San Carlos Madrid, Spain